Answers are grounded in this paper and cite their sources.
Use of adjuvant immune checkpoint inhibitors (ICIs) following non‑small cell lung cancer (NSCLC) resection has been studied; however, assessing their benefit‑risk profile requires considering recurrence control, survival evidence and toxicity together. The present study reviewed randomized trial evidence for postoperative adjuvant ICI therapy. In this PROSPERO‑registered systematic review reported according to Preferred Reporting Items for Systematic Reviews and Meta‑Analyses guidelines, five databases were searched. Eligible trials evaluated postoperative adjuvant ICI therapy compared against non‑ICI management; studies of neoadjuvant‑only or combined neoadjuvant‑adjuvant perioperative regimens were excluded. Disease‑free survival (DFS) was the primary endpoint. Primary DFS inference was based on Hartung‑Knapp (HK)‑adjusted confidence intervals and tests within a DerSimonian‑Laird random‑effects model; conventional intervals provided a comparison. Safety outcomes were assessed separately. Four randomized controlled trials (IMpower010, KEYNOTE‑091/PEARLS, BR.31, EA5142/ANVIL; n=4,336) provided DFS data. The primary analysis with HK adjustment yielded a hazard ratio (HR) of 0.86 [95% confidence interval (CI), 0.74‑1.01; P=0.0618; I²=15.0%], with the interval encompassing no effect. Conventional Wald inference produced an identical HR but a narrower 95% CI (0.78‑0.95; P=0.0035). Three compatible broad‑population overall survival (OS) estimates were subjected to an exploratory synthesis, but no survival benefit was established (HR, 0.96; 95% CI, 0.84‑1.10; P=0.5823; I²=0.0%). The point estimates for trial‑reported high‑grade adverse events of any cause [risk ratio (RR), 1.45; conventional 95% CI, 1.18‑1.78; HK 95% CI, 0.88‑2.38] and serious adverse events (RR, 1.60; conventional 95% CI, 1.27‑2.01; HK 95% CI, 0.94‑2.73) were both >1, whereas the corresponding HK intervals encompassed 1. Deaths attributed to treatment occurred in 14 of 2,022 ICI‑treated patients and 0 of 1,539 control patients across the three trials with comparative safety data. In conclusion, adjuvant ICI may improve DFS after complete resection of NSCLC, but the conservative model cannot rule out no benefit. An OS benefit has not been established. Following upfront surgery, the possibility of reducing recurrence with adjuvant ICI is weighed against treatment‑related toxicity.
No takes yet. Share an insight, caveat, or question.
Mao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: